BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
Stocks · News reference
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser after CFO resignation.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%
On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with Creative Acquisition Corp. ("CAC"),
8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Filed: 2026-09-25 AccNo: 0001477932-26-005805 Size: 163 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the